<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804257297
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pinolanz
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        126.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPIRO PHARMA LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPIRO PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pinolanz contains the active substance olanzapine. Pinolanz belongs to a group of medicines called antipsychotics and is used to treat schizophrenia - a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense.</p><p>Pinolanz is for injection IntraMuscular is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.</p><p>&ldquo;Psychomotor agitation&rdquo; is defined in DSM-IV as &ldquo;excessive motor activity associated with a feeling of inner tension.&rdquo; Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self- exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Pinolanz if you have:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; an allergy (hypersensitivity) to olanzapine or any of the other ingredients of this medicine (listed in section 6). <strong>An allergic reaction </strong>may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your nurse or doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp; been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).</p><p>Warnings and precautions</p><p>Talk to your doctor or nurse before you are given Pinolanz.</p><p>Elderly Patients with Dementia-Related Psychosis</p><p>Increased Mortality &mdash; Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.</p><p>Olanzapine for injection is not approved for the treatment of patients with dementia-related psychosis.</p><p>Cerebrovascular Adverse Events (CVAE), Including Stroke &mdash; Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis.</p><p>Suicide</p><p>The possibility of a suicide attempt is inherent in schizophrenia and in bipolar I disorder, and close supervision of high-risk patients should accompany drug therapy.</p><p>Prescriptions for olanzapine should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.</p><p>Neuroleptic Malignant Syndrome (NMS)</p><p>A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including olanzapine.</p><p>Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p><p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with olanzapine exposure. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue olanzapine if DRESS is suspected.</p><p>&nbsp;</p><p>Metabolic Changes</p><p>Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk.</p><p>Dyslipidemia</p><p>Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using olanzapine, is recommended.</p><p>Weight Gain</p><p>Potential consequences of weight gain should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight.</p><p>Tardive Dyskinesia</p><p>A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.</p><p>The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.</p><p>However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.</p><p>Tardive dyskinesia may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long- term course of the syndrome is unknown.</p><p>Given these considerations, olanzapine should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients (1) who suffer from a chronic illness that is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p><p>If signs and symptoms of tardive dyskinesia appear in a patient on olanzapine, drug discontinuation should be considered. However, some patients may require treatment with olanzapine despite the presence of the syndrome.</p><p>Orthostatic Hypotension</p><p>Olanzapine may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its &alpha;1- adrenergic antagonistic properties.</p><p>The risk for this sequence of hypotension, bradycardia, and sinus pause may be greater in nonpsychiatric patients compared to psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs. For intramuscular olanzapine for injection therapy, patients should remain recumbent if drowsy or dizzy after injection until examination has indicated that they are not experiencing postural hypotension, bradycardia, and/or hypoventilation.</p><p>&nbsp;</p><p>Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk.</p><p>Caution is necessary in patients who receive treatment with other drugs having effects that can induce hypotension, bradycardia, respiratory or central nervous system depression. Concomitant administration of intramuscular olanzapine and parenteral benzodiazepine is not recommended due to the potential for excessive sedation and cardiorespiratory depression.</p><p>Falls</p><p>Olanzapine may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</p><p>Leukopenia, Neutropenia, and Agranulocytosis</p><p>Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of Pinolanz should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt;1000/mm 3) should discontinue Pinolanz and have their WBC followed until recovery.</p><p>Dysphagia</p><p>Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer&rsquo;s disease. Pinolanz is not approved for the treatment of patients with Alzheimer&rsquo;s disease.</p><p>Seizures</p><p>Pinolanz should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer&rsquo;s dementia. Pinolanz is not approved for the treatment of patients with Alzheimer&rsquo;s disease. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.</p><p>Potential for Cognitive and Motor Impairment</p><p>Somnolence was a commonly reported adverse reaction associated with Pinolanz treatment. This adverse reaction was also dose related.</p><p>Since Pinolanz has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Pinolanz therapy does not affect them adversely.</p><p>&nbsp;</p><p>Body Temperature Regulation</p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing Pinolanz for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.</p><p>Anticholinergic (antimuscarinic) Effects</p><p>Pinolanz should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, constipation, or a history of paralytic ileus or related conditions.</p><p>Hyperprolactinemia</p><p>As with other drugs that antagonize dopamine D 2 receptors, Pinolanz elevates prolactin levels, and the elevation persists during chronic administration.</p><p>Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin- elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.</p><p>&nbsp;</p><p>Children and adolescents</p><p><strong>Pinolanz is not for patients who are under 18 years.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Pinolanz</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor if you are taking:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for Parkinson&rsquo;s disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine (an anti-epileptic and mood stabilizer), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Pinolanz dose.</p><p>If you are already taking antidepressants, medicines for anxiety or to help you sleep (tranquillizers), you may feel drowsy if Pinolanz is given.</p><p>Pinolanz with alcohol</p><p>Do not drink any alcohol if you have been given Pinolanz as together with alcohol it may make you feel drowsy.</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this injection.</p><p>You should not be given this injection if you are breast-feeding as small amounts of olanzapine can pass into breast milk.</p><p>The following symptoms may occur in new born babies, of mothers that have used Pinolanz in the last</p><p>&nbsp;</p><p>trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>Driving and using machines</p><p>Do not drive or operate machinery for the remainder of the day after each injection.</p><p>Pinolanz contains sodium</p><p>After reconstitution this medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide how much Pinolanz you need and how often you need to be given an injection. 2.4Olanzapine for injection: Agitation Associated with Schizophrenia and Bipolar I Mania</p><p>Dose Selection for Agitated Adult Patients with Schizophrenia and Bipolar I Mania &mdash; The efficacy of intramuscular olanzapine for injection in controlling agitation in these disorders was demonstrated in a dose range of 2.5 mg to 10 mg. The recommended dose in these patients is 10 mg. A lower dose of 5 or</p><p>7.5 mg may be considered when clinical factors warrant. If agitation warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. However, the efficacy of repeated doses of intramuscular olanzapine for injection in agitated patients has not been systematically evaluated in controlled clinical trials. Also, the safety of total daily doses greater than 30 mg, or 10 mg injections given more frequently than 2 hours after the initial dose, and 4 hours after the second dose have not been evaluated in clinical trials. Maximal dosing of intramuscular olanzapine (e.g., 3 doses of 10 mg administered 2 to 4 hours apart) may be associated with a substantial occurrence of significant orthostatic hypotension. Thus, it is recommended that patients requiring subsequent intramuscular injections be assessed for orthostatic hypotension prior to the administration of any subsequent doses of intramuscular olanzapine for injection. The administration of an additional dose to a patient with a clinically significant postural change in systolic blood pressure is not recommended.</p><p>If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5 to 20 mg/day as soon as clinically appropriate.</p><p>Intramuscular Dosing in Special Populations &mdash; A dose of 5 mg/injection should be considered for geriatric patients or when other clinical factors warrant. A lower dose of</p><p>2.5 mg/injection should be considered for patients who otherwise might be debilitated, be predisposed to hypotensive reactions, or be more pharmacodynamically sensitive to olanzapine.</p><p>&nbsp;</p><p>Administration of olanzapine for injection &mdash; Olanzapine for injection Intramuscular is intended for intramuscular use only. Do not administer intravenously or subcutaneously. Inject slowly, deep into the muscle mass.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p><p>Directions for Preparation of olanzapine for injection Intramuscular with Sterile Water for Injection &mdash; Dissolve the contents of the vial using 2.1 mL of Sterile Water for Injection to provide a solution containing approximately 5 mg/mL of olanzapine. The resulting solution should appear clear and yellow. Olanzapine for injection Intramuscular reconstituted with Sterile Water for Injection should be used immediately (within 1 hour) after reconstitution. Discard any unused portion.</p><p>The following table provides injection volumes for delivering various doses of intramuscular olanzapine for injection reconstituted with Sterile Water for Injection.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose, mg Olanzapine</p></td><td style="vertical-align:top"><p>Volume of Injection, mL</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>Withdraw total contents of vial</p></td></tr><tr><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>0.5</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Physical Incompatibility Information &mdash; Olanzapine for injection IntraMuscular should be reconstituted only with Sterile Water for Injection. Olanzapine for injection IntraMuscular should not be combined in a syringe with diazepam injection because precipitation occurs when these products are mixed. Lorazepam injection should not be used to reconstitute olanzapine for injection IntraMuscular as this combination results in a delayed reconstitution time. Olanzapine for injection IntraMuscular should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time.If you are given more Pinolanz than needed</p><p>This medicine will be given to you under medical supervision, it is therefore unlikely that you will be given too much.</p><p>Patients who have been given too much olanzapine have also experienced the following symptoms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.</p><p>&nbsp;</p><p>Other symptoms may include:</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness, and drowsiness or sleepiness; slower breathing, aspiration, high or low blood pressure, abnormal rhythms of the heart.</p><p><strong>Contact your doctor or hospital straight away if you experience any of the above symptoms. </strong>Do not stop your treatment just because you feel better. It is important that you carry on receiving Pinolanz for as long as your doctor has told you to.</p><p>If you miss an injection, you should contact your doctor to arrange your next injection as soon as you can.</p><p>Pinolanz Intra Muscular: Agitation Associated with Schizophrenia and Bipolar I Mania</p><p>Dose Selection for Agitated Adult Patients with Schizophrenia and Bipolar I Mania - The efficacy of intramuscular olanzapine for injection in controlling agitation in these disorders was demonstrated in a dose range of 10 mg. The recommended dose in these patients is 10 mg.</p><p>A lower dose may be considered when clinical factors warrant. If agitation warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. However, the efficacy of repeated doses of intramuscular olanzapine for injection in agitated patients has not been systematically evaluated in controlled clinical trials. Also, the safety of total daily doses greater than 30 mg, or 10 mg injections given more frequently than 2 hours after the initial dose, and 4 hours after the second dose have not been evaluated in clinical trials. Maximal dosing of intramuscular olanzapine (e.g., 3 doses of 10 mg administered 2-4 hours apart) may be associated with a substantial occurrence of significant orthostatic hypotension. Thus, it is recommended that patients requiring subsequent intramuscular injections be assessed for orthostatic hypotension prior to the administration of any subsequent doses of intramuscular olanzapine for injection. The administration of an additional dose to a patient with a clinically significant postural change in systolic blood pressure is not recommended</p><p>If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5-20 mg/day as soon as clinically appropriate.</p><p>Intramuscular Dosing in Special Populations &mdash; A dose of 5 mg/injection should be considered for geriatric patients or when other clinical factors warrant. A lower dose should be considered for patients who otherwise might be debilitated, be predisposed to hypotensive reactions, or be more pharmacodynamically sensitive to olanzapine.</p><p>Administration of Pinolanz IntraMuscular &mdash; Pinolanz IntraMuscular is intended for intramuscular use only. Do not administer intravenously or subcutaneously.</p><p>Inject slowly, deep into the muscle mass.</p><p>&nbsp;</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to</p><p>administration, whenever solution and container permit</p><p>Directions for Preparation of Pinolanz IntraMuscular with Sterile Water for Injection &mdash; Dissolve the contents of the vial using 2.1 mL of Sterile Water for Injection to provide a solution containing approximately 5 mg/mL of olanzapine. The resulting solution should appear clear and yellow. Pinolanz IntraMuscular reconstituted with Sterile Water for Injection should be used immediately (within 1 hour) after reconstitution. Discard any unused portion</p><p>The following table provides injection volumes for delivering various doses of intramuscular olanzapine for injection reconstituted with Sterile Water for Injection</p><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:377.45pt;margin-top:12.6pt;width:3pt;height:.6pt;z-index:251658240;
 mso-position-horizontal-relative:page' fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="4" height="1" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Dose, mg Olanzapin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume of Injection, mL Withdraw total contents of vial</p><p>10 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5mL</p><p>Physical Incompatibility Information &mdash; Pinolanz IntraMuscular should be reconstituted only with Sterile Water for Injection. Pinolanz IntraMuscular should not be combined in a syringe with diazepam injection because precipitation occurs when these products are mixed. Lorazepam injection should not be used to reconstitute Pinolanz IntraMuscular as this combination results in a delayed reconstitution time. Pinolanz IntraMuscular should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor immediately if you have:</p><p>&bull;&nbsp;&nbsp;&nbsp; excessive sleepiness, dizziness, confusion, disorientation, difficulty talking, difficulty walking, muscle stiffness or shaking, weakness, irritability, aggression, anxiety, increase in blood pressure, or convulsions and can lead to unconsciousness. These signs and symptoms can sometimes occur as a result of Pinolanz entering the bloodstream too quickly (a common side effect that may affect up to1 in10 people);</p><p>&bull;&nbsp;&nbsp;&nbsp; unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;</p><p>&bull;&nbsp;&nbsp;&nbsp; blood clots in the veins (an uncommon side effect that may affect up to 1in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).</p><p>&nbsp;</p><p>Other common side effects (may affect up to 1 in 10 people) with Pinolanz include sleepiness and injection site pain.</p><p>Rare side effects (may affect up to 1 in 1000 people) with Pinolanz include injection site infection.</p><p>The side effects listed below have been observed when oral olanzapine has been given but may occur following administration of Pinolanz.</p><p>Other very common side effects (may affect more than 1 in 10 people) include weight gain; and increases in levels of prolactin in the blood. In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.</p><p>Other common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and in early treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.</p><p>Other uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching; rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose: abdominal distension; drooling; memory loss or forgetfulness; urinary incontinence; lack of ability to such as an abnormal production of breast milk or abnormal growth.</p><p>Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection. Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen on blood tests and an increase in a type of white blood cells (eosinophilia).</p><p>&nbsp;</p><p>While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients. In patients with Parkinson&#39;s disease oral olanzapine may worsen the symptoms.</p><p>Adverse Reactions Associated with the Use of Olanzapine in SCHIZOPHRENIA:</p><p>Postural hypotension, Constipation, Weight gain, Dizziness, Personality disorder a, Akathisia.</p><p>Adverse Reactions Associated with the Use Olanzapine in Bipolar I Disorder (Manic or Mixed Episodes)</p><p>Asthenia, Dry mouth, Constipation, Dyspepsia, Increased appetite, Somnolence, Dizziness, Tremor. <u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If any of side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist.</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia<em>:</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:14.95pt;width:382.6pt;height:98.35pt;z-index:-251657216;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-14.35pt;
     mso-list:l0 level1 lfo2;tab-stops:14.2pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>The National
     Pharmacovigilance and Drug Safety Centre<span style='letter-spacing:-.5pt'>
     </span>(NPC)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:8.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.65pt;
     mso-list:l0 level2 lfo2;tab-stops:14.2pt'><![if !supportLists]><span
     style='font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA Call Center:<span style='letter-spacing:-.2pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:9.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.65pt;
     mso-list:l0 level2 lfo2;tab-stops:14.2pt'><![if !supportLists]><span
     style='font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.05pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:9.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.65pt;
     mso-list:l0 level2 lfo2;tab-stops:14.2pt'><![if !supportLists]><span
     style='font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><span
     style='color:blue'>https://ade.sfda.gov.sa/</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="515" height="135" alt="Text Box: •	The National Pharmacovigilance and Drug Safety Centre (NPC)
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:90pt;
  margin-top:10.4pt;width:431.15pt;height:22.6pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".96pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:22.9pt;text-indent:-18.3pt;
     line-height:14.1pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo1;
     tab-stops:22.9pt 22.95pt'><![if !supportLists]><span style='font-family:
     Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Please contact the
     relevant competent<span style='letter-spacing:-.25pt'> </span>authority.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="579" height="35" alt="Text Box: -	Please contact the relevant competent authority." src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitution Temperature (20-25&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitution (20-25&deg;C) with 2.1 mL of sterile water for injection, each mL will contain 5 mg of Olanzapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shelf life: 24 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Reconstitution: </strong>Pinolanz is found stable for 1 hour at room temperature ( 20-25&deg;C) with sterile water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Pinolanz contains</p><p>The active substance is Olanzapine. Each vial contains Olanzapine 10 mg. <strong>The other ingredients are:</strong></p><p>Tartaric Acid, Lactose monohydrate, Sodium Hydroxide, Hydrochloric acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Pinolanz looks like?
Yellow color lyophilized cake or powder
After reconstitution - Clear Yellow colored solution.
How supplied:
Pinolanz Injections are supplied in Tubular glass Vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p><strong>Saudi Amarox Industrial Company </strong>Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850</p><p>Manufacturer</p><p>Aspiro Pharma Limited - India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May-2024, Version 1. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بينولانز على المادة الفعالة أولانزابين. وينتمي بينولانز إلى مجموعة من الأدوية تسمى مضادات الذهان ويستخدم لعلاج الفصام - وهو مرض له أعراض مثل السمع أو الرؤية أو الإحساس بأشياء غير موجودة، والمعتقدات الخاطئة، والشك غير المعتاد، والانسحاب. قد يشعر الأشخاص المصابون بهذا المرض أيضًا بالاكتئاب أو القلق أو التوتر.</p><p dir="RTL">يستخدم بينولانز للحقن العضلي لعلاج الهياج الحاد المرتبط بالفصام والهوس ثنائي القطب I (من النوع الأول).</p><p dir="RTL">يتم تعريف &quot;الإثارة الحركية النفسية&quot; في الدليل التشخيصي والإحصائي للاضطرابات العقلية - الطبعة الرابعة (DSM-IV) على أنها &quot;نشاط حركي مفرط مرتبط بالشعور بالتوتر الداخلي&quot;. غالبًا ما يظهر المرضى الذين يعانون من الانفعالات سلوكيات تتعارض مع تشخيصهم ورعايتهم، على سبيل المثال، سلوكيات التهديد، أو السلوك التصعيدي أو المؤلم بشكل عاجل، أو السلوك المرهق للذات، مما يدفع الأطباء إلى استخدام الأدوية المضادة للذهان العضلية لتحقيق السيطرة الفورية على الانفعالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استخدام بينولانز في الحالات التالية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (الحساسية الشديدة) تجاه أولانزابين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6). يمكن التعرف <strong>على رد الفعل التحسسي </strong>على أنه طفح جلدي أو حكة أو تورم في الوجه أو تورم في الشفاه أو ضيق في التنفس. إذا حدث هذا لك، أخبر ممرضتك أو طبيبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم تشخيصك سابقاً بمشاكل في العين مثل أنواع معينة من الجلوكوما (زيادة الضغط في العين).</p><p>التحذيرات والاحتياطات</p><p dir="RTL">تحدث إلى طبيبك أو ممرضتك قبل إعطائك بينولانز في الحالات التالية:</p><p>المرضى المسنين الذين يعانون من الذهان المرتبط بالخرف</p><p dir="RTL">زيادة معدل الوفيات - المرضى المسنون المصابون بالذهان المرتبط بالخرف والذين يعالجون بالأدوية المضادة للذهان هم أكثر عرضة للوفاة.</p><p dir="RTL">لم تتم الموافقة على استخدام أولانزابين للحقن لعلاج المرضى الذين يعانون من الذهان المرتبط بالخرف.</p><p dir="RTL">تم الإبلاغ عن الأحداث الضارة الدماغية الوعائية (CVAE)، بما في ذلك السكتة الدماغية - تم الإبلاغ عن الأحداث الضارة الوعائية الدماغية (مثل السكتة الدماغية والنوبات الإقفارية العابرة)، بما في ذلك الوفيات، في المرضى في تجارب عقار أولانزابين في المرضى المسنين المصابين بالذهان المرتبط بالخرف.</p><p dir="RTL"><strong>الانتحار</strong></p><p dir="RTL">إن احتمالية محاولة الانتحار أمر متأصل في مرض انفصام الشخصية والاضطراب ثنائي القطب I (من النوع الأول)، ويجب أن يصاحب العلاج الدوائي الإشراف الدقيق على المرضى المعرضين لمخاطر عالية.</p><p dir="RTL">ينبغي وصف أدوية أولانزابين بأقل كمية من الأقراص التي تتوافق مع الاستجابة الجيدة للمريض، وذلك لتقليل خطر الجرعة الزائدة.</p><p dir="RTL"><strong>متلازمة الذهان الخبيثة</strong><strong> (NMS)</strong></p><p dir="RTL">تم الإبلاغ عن مجموعة من الأعراض القاتلة التي يشار إليها أحيانًا باسم متلازمة الذهان الخبيثة (NMS) بالاشتراك مع تناول الأدوية المضادة للذهان، بما في ذلك أولانزابين. الأعراض السريرية لـ NMS هي فرط الحرارة، وتصلب العضلات، وتغير الحالة العقلية والدليل على عدم الاستقرار اللاإرادي (عدم انتظام النبض أو ضغط الدم، عدم انتظام دقات القلب، تعرق غزير، وعدم انتظام ضربات القلب). قد تشمل الأعراض الإضافية ارتفاع فسفوكيناز الكرياتينين، (البيلة الميوجلوبينيَّة myoglobinuria) (انحلال الربيدات)، والفشل الكلوي الحاد.</p><p dir="RTL">يجب أن تشمل طريقة التعامل مع حالة NMS ما يلي: 1) الإيقاف الفوري للأدوية المضادة للذهان والأدوية الأخرى غير الضرورية للعلاج المتزامن. 2) علاج الأعراض المكثف والمراقبة الطبية. و 3) علاج أي مشاكل طبية خطيرة مصاحبة تتوفر لها علاجات محددة.</p><p dir="RTL"><strong>التفاعل الدوائي مع كثرة اليوزينيات (الحمضات) والأعراض الجهازية</strong><strong> (DRESS)</strong></p><p dir="RTL">تم الإبلاغ عن تفاعل دوائي مع فرط الحمضات والأعراض الجهازية (DRESS) عند التعرض لدواء لأولانزابين. قد يظهر DRESS مع تفاعل جلدي (مثل الطفح الجلدي أو التهاب الجلد التقشري)، وفرط الحمضات، والحمى، و/أو تضخم العقد اللمفية مع مضاعفات جهازية مثل التهاب الكبد، والتهاب الكلية، والتهاب الرئة، والتهاب عضلة القلب، و/أو التهاب التامور (تورم وتهيُّج في الغشاء الرقيق الشبيه بالجيب المحيط بالقلب). (DRESS) في بعض الأحيان قاتلة. توقف عن تناول عقار أولانزابين في حالة الاشتباه في تناول DRESS.</p><p dir="RTL"><strong>التغيرات الأيضية</strong></p><p dir="RTL">ارتبطت الأدوية المضادة للذهان غير التقليدية بالتغيرات الأيضية بما في ذلك ارتفاع السكر في الدم، واضطراب شحوم الدم، وزيادة الوزن. قد تترافق التغيرات الأيضية مع زيادة خطر الإصابة بأمراض القلب والأوعية الدموية/الدماغية.</p><p dir="RTL"><strong>عسر شحميات الدم</strong></p><p dir="RTL">وقد لوحظت تغيرات غير مرغوب فيها في نسبة الدهون عند استخدام عقار أولانزابين. يوصى بالمراقبة السريرية، بما في ذلك تقييمات الدهون الأساسية والمتابعة الدورية لدى المرضى الذين يستخدمون عقار أولانزابين.</p><p dir="RTL"><strong>زيادة الوزن</strong></p><p dir="RTL">ينبغي النظر في العواقب المحتملة لزيادة الوزن قبل البدء بتناول عقار أولانزابين. يجب أن يتلقى المرضى الذين يستخدمون عقار أولانزابين مراقبة منتظمة للوزن.</p><p dir="RTL"><strong>خلل الحركة المتأخر</strong></p><p dir="RTL">قد تتطور متلازمة حركات خلل الحركة اللاإرادية التي لا رجعة فيها في المرضى الذين يعالجون بأدوية مضادة للذهان. على الرغم من أن انتشار المتلازمة يبدو أعلى بين كبار السن، وخاصة النساء المسنات، فمن المستحيل الاعتماد على تقديرات الانتشار للتنبؤ، في بداية العلاج المضاد للذهان، بالمرضى الذين من المحتمل أن يصابوا بالمتلازمة. من غير المعروف ما إذا كانت منتجات الأدوية المضادة للذهان تختلف في قدرتها على التسبب في خلل الحركة المتأخر.</p><p dir="RTL">يُعتقد أن خطر الإصابة بخلل الحركة المتأخر واحتمال أن يصبح غير قابل للعلاج يزداد مع زيادة مدة العلاج والجرعة التراكمية الإجمالية للأدوية المضادة للذهان المعطاة للمريض.</p><p dir="RTL">ومع ذلك، يمكن أن تتطور المتلازمة، على الرغم من أنها أقل شيوعًا، بعد فترات علاج قصيرة نسبيًا بجرعات منخفضة أو قد تنشأ حتى بعد التوقف عن العلاج.</p><p dir="RTL">قد يهدأ خلل الحركة المتأخر، جزئيًا أو كليًا، إذا تم سحب العلاج المضاد للذهان. ومع ذلك، فإن العلاج المضاد للذهان في حد ذاته قد يقمع (أو يقمع جزئيًا) علامات وأعراض المتلازمة، وبالتالي قد يخفي العملية الأساسية. إن تأثير كبت الأعراض على المسار طويل الأمد للمتلازمة غير معروف.</p><p dir="RTL">ونظراً لهذه الاعتبارات، ينبغي وصف عقار أولانزابين بطريقة من المرجح أن تقلل من حدوث خلل الحركة المتأخر. يجب عمومًا أن يقتصر العلاج المضاد للذهان المزمن للمرضى (1) الذين يعانون من مرض مزمن معروف باستجابته للأدوية المضادة للذهان، و (2) الذين لا تتوفر أو مناسبة لهم علاجات بديلة متساوية الفعالية ولكنها أقل ضررًا. في المرضى الذين يحتاجون إلى علاج مزمن، يجب البحث عن أصغر جرعة وأقصر مدة علاج التي تؤدي إلى استجابة سريرية مرضية. يجب إعادة تقييم الحاجة لاستمرار العلاج بشكل دوري.</p><p dir="RTL">إذا ظهرت علامات وأعراض خلل الحركة المتأخر لدى مريض يتناول عقار أولانزابين، فيجب النظر في وقف الدواء. ومع ذلك، قد يحتاج بعض المرضى إلى العلاج باستخدام أولانزابين على الرغم من وجود المتلازمة.</p><p dir="RTL"><strong>هبوط ضغط الدم الانتصابي</strong></p><p dir="RTL">قد يسبب أولانزابين انخفاض ضغط الدم الانتصابي المرتبط بالدوار، عدم انتظام دقات القلب، بطء القلب، وفي بعض المرضى، الإغماء، خاصة خلال فترة معايرة الجرعة الأولية، مما يعكس على الأرجح خصائصه المضادة للأدرينالية &alpha;1.</p><p dir="RTL">قد يكون خطر هذا التتابع من انخفاض ضغط الدم وبطء القلب توقف العقدة الجيبية الأنفية أكبر لدى المرضى غير المصابين بأمراض نفسية مقارنة بالمرضى النفسيين الذين ربما يكونون أكثر تكيفًا مع تأثيرات معينة للأدوية العقلية. بالنسبة إلى أولانزابين للحقن العضلي، يجب أن يظل المرضى مستلقين إذا شعروا بالنعاس أو الدوار بعد الحقن حتى يشير الفحص إلى أنهم لا يعانون من انخفاض ضغط الدم الوضعي و/أو بطء القلب و/أو نقص التهوية.</p><p dir="RTL">يجب استخدام أولانزابين بحذر خاص في المرضى الذين يعانون من أمراض القلب والأوعية الدموية المعروفة (تاريخ احتشاء عضلة القلب أو نقص التروية، قصور القلب، أو تشوهات التوصيل)، والأمراض الدماغية الوعائية، والحالات التي قد تهيئ المرضى لانخفاض ضغط الدم (الجفاف، ونقص حجم الدم، والعلاج بالأدوية الخافضة للضغط).) حيث أن حدوث الإغماء أو انخفاض ضغط الدم و/أو بطء القلب قد يعرض المريض لخطر طبي متزايد.</p><p dir="RTL">يجب توخي الحذر عند المرضى الذين يتلقون العلاج بأدوية أخرى لها تأثيرات يمكن أن تؤدي إلى انخفاض ضغط الدم أو بطء القلب أو اكتئاب الجهاز التنفسي أو الجهاز العصبي المركزي. لا ينصح الاستخدام المتزامن لدواء أولانزابين للحقن العضلي وبنزوديازيبين للحقن بسبب احتمالية التخدير المفرط والاكتئاب القلبي التنفسي.</p><p dir="RTL"><strong>السقوط</strong></p><p dir="RTL">قد يسبب أولانزابين النعاس، وانخفاض ضغط الدم الوضعي، عدم الاستقرار الحركي والحسي، مما قد يؤدي إلى السقوط، وبالتالي الكسور أو الإصابات الأخرى. بالنسبة للمرضى الذين يعانون من أمراض أو حالات أو يتناولون أدوية يمكن أن تؤدي إلى تفاقم هذه التأثيرات، يجب إجراء تقييمات كاملة لمخاطر السقوط عند بدء العلاج باستخدام المضاد للذهان وبشكل متكرر للمرضى الذين يخضعون للعلاج طويل الأمد بمضادات الذهان.</p><p dir="RTL"><strong>قلة الكريات البيض، قلة العدلات، وندرة المحببات</strong></p><p dir="RTL">تشمل عوامل الخطر المحتملة لنقص الكريات البيض/قلة العدلات انخفاض عدد خلايا الدم البيضاء (WBC) الموجود مسبقًا وتاريخ نقص الكريات البيض/قلة العدلات الناجم عن بعض الأدوية. يجب مراقبة تعداد الدم الكامل (CBC) بشكل متكرر خلال الأشهر القليلة الأولى من العلاج للمرضى الذين لديهم تاريخ من انخفاض ملحوظ في عدد كريات الدم البيضاء أو نقص الكريات البيض / قلة العدلات الناجم عن الأدوية، وينبغي النظر في وقف تناول بينولانز عند أول علامة على انخفاض ملحوظ سريريًا في WBC في غياب العوامل المسببة الأخرى.</p><p dir="RTL">يجب مراقبة المرضى الذين يعانون من قلة العدلات بشكل ملحوظ سريريًا بعناية بحثًا عن الحمى أو غيرها من الأعراض أو علامات العدوى وعلاجهم على الفور في حالة ظهور مثل هذه الأعراض أو العلامات. يجب على المرضى الذين يعانون من قلة العدلات الشديدة (عدد العدلات المطلق &lt;1000 / مم<sup>3</sup>) التوقف عن تناول بينولانز ومتابعة كريات الدم البيضاء لديهم حتى الشفاء.</p><p dir="RTL"><strong>عسر البلع</strong></p><p dir="RTL">ارتبط خلل الحركة المريئي ومجرى الهواء باستخدام الأدوية المضادة للذهان. الالتهاب الرئوي ومجرى الهواء هو سبب شائع للإصابة بالمرض والوفيات لدى المرضى الذين يعانون من مرض الزهايمر المتقدم. لم تتم الموافقة على استخدام بينولانز لعلاج مرضى الزهايمر.</p><p dir="RTL"><strong>النوبات</strong></p><p dir="RTL">ينبغي استخدام بينولانز بحذر في المرضى الذين لديهم تاريخ من النوبات أو الذين يعانون من حالات من المحتمل أن تخفض معدلات النوبات، على سبيل المثال، خرف الزهايمر. لم تتم الموافقة على استخدام بينولانز لعلاج مرضى الزهايمر. قد تكون الحالات التي تخفض معدلات النوبات أكثر انتشارًا لدى السكان الذين يبلغ عمرهم 65 عامًا أو أكثر.</p><p dir="RTL"><strong>احتمالية الإصابة بالضعف المعرفي والحركي</strong></p><p dir="RTL">كان النعاس أحد الآثار الجانبية الشائعة المرتبطة بالعلاج باستخدام بينولانز. كان هذا التفاعل السلبي مرتبطًا أيضًا بالجرعة.</p><p dir="RTL">نظرًا لأن بينولانز لديه القدرة على إضعاف الحكم أو التفكير أو المهارات الحركية، فيجب تحذير المرضى بشأن تشغيل الآلات الخطرة، بما في ذلك السيارات، حتى يتأكدوا بشكل معقول من أن علاج بينولانز لا يؤثر عليهم بشكل سلبي.</p><p dir="RTL"><strong>تنظيم درجة حرارة الجسم</strong></p><p dir="RTL">يرجع اضطراب قدرة الجسم على خفض درجة حرارة الجسم الأساسية إلى العوامل المضادة للذهان. يُنصح بالرعاية المناسبة عند وصف بينولانز للمرضى الذين سيعانون من حالات قد تساهم في ارتفاع درجة حرارة الجسم الأساسية، على سبيل المثال، ممارسة التمارين الرياضية بقوة، أو التعرض للحرارة الشديدة، أو تلقي أدوية مصاحبة مع نشاط مضاد للكولين، أو التعرض للجفاف.</p><p dir="RTL"><strong>تأثيرات مضادات الكولين (مضادات المسكارين).</strong></p><p dir="RTL">يجب استخدام بينولانز بحذر عند المرضى الذين لديهم تشخيص حالي أو تاريخ سابق لاحتباس البول، أو تضخم البروستاتا المهم سريريًا، أو الإمساك، أو تاريخ من العلوص الشللي أو الحالات ذات الصلة.</p><p dir="RTL"><strong>فرط برولاكتين الدم</strong></p><p dir="RTL">كما هو الحال مع الأدوية الأخرى من مضادات مستقبلات الدوبامين D 2، يرفع بينولانز مستويات البرولاكتين، ويستمر الارتفاع أثناء تناوله بشكل مزمن.</p><p dir="RTL">قد يؤدي فرط برولاكتين الدم إلى تثبيط هرمون GnRH منطقة تحت المهاد، مما يؤدي إلى انخفاض إفراز الغدد التناسلية النخامية. وهذا بدوره قد يمنع الوظيفة الإنجابية عن طريق إضعاف تكوين الستيرويدات التناسلية لدى المرضى من الإناث والذكور. تم الإبلاغ عن ثر اللبن، وانقطاع الطمث، والتسدي، والعجز الجنسي لدى المرضى الذين يتلقون أدوية ترفع البرولاكتين. فرط برولاكتين الدم طويل الأمد عندما يرتبط بقصور الغدد التناسلية قد يؤدي إلى انخفاض كثافة العظام في كل من الإناث والذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>يجب عدم استخدام بينولانز للمرضى الذين تقل أعمارهم عن 18 عاما.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى وبينولانز</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. على وجه الخصوص، أخبر طبيبك إذا كنت تتناول:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لمرض باركنسون.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (مضاد للصرع ومثبت للمزاج)، فلوفوكسامين (مضاد للاكتئاب) أو سيبروفلوكساسين (مضاد حيوي) - قد يكون من الضروري تغيير جرعة بينولانز.</p><p dir="RTL">إذا كنت تتناول بالفعل أدوية من مضادات الاكتئاب أو أدوية للقلق أو أدوية لمساعدتك على النوم (المهدئات)، فقد تشعر بالنعاس إذا تم إعطاءك بينولانز.</p><p>تناول بينولانز مع الكحول</p><p dir="RTL">يجب عدم شرب أي كحول إذا تم إعطاؤك بينولانز لأن تناوله مع الكحول قد يجعلك تشعر بالنعاس.</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنت حاملاً أو مرضعة، تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، اطلبي من طبيبك النصيحة قبل إعطائك هذا الدواء.</p><p dir="RTL">لا ينبغي إعطاؤك هذه الحقنة إذا كنت ترضعين طفلك رضاعة طبيعية لأن كميات صغيرة من أولانزابين يمكن أن تنتقل إلى حليب الثدي.</p><p dir="RTL">قد تظهر الأعراض التالية عند الأطفال حديثي الولادة، من الأمهات اللاتي استخدمن بينولانز في الأشهر الثلاثة الأخيرة (الأشهر الثلاثة الأخيرة من الحمل): اهتزاز، تصلب و/أو ضعف العضلات، النعاس، الإثارة، مشاكل في التنفس، وصعوبة في التغذية. إذا ظهر على طفلك أي من هذه الأعراض، فقد تحتاجين إلى الاتصال بطبيبك.</p><p>القيادة واستخدام الآلات</p><p dir="RTL">يجب عدم قيادة السيارة أو تشغل الآلات لبقية اليوم بعد كل حقنة.</p><p>بينولانز يحتوي على الصوديوم</p><p dir="RTL">بعد إعادة تحضير المحلول، يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملجرام) لكل قارورة، أي خال من الصوديوم بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقرر طبيبك مقدار دواء بينولانز الذي تحتاجه وعدد المرات التي تحتاج فيها إلى الحقن.</p><p dir="RTL">أولانزابين للحقن: الإثارة المرتبطة بالفصام والهوس ثنائي القطب I</p><p dir="RTL">اختيار الجرعة للمرضى البالغين المضطربين المصابين بالفصام والهوس ثنائي القطب I - تم إثبات فعالية أولانزابين للحقن العضلي في السيطرة على الانفعالات في هذه الاضطرابات في نطاق جرعة يتراوح بين 2.5 ملجرام إلى 10 ملجرام. الجرعة الموصى بها لهؤلاء المرضى هي 10 ملجرام. يمكن النظر في جرعة أقل قدرها 5 أو 7.5 ملجرام عندما تتطلب العوامل السريرية ذلك. إذا استمر الإثارة التي تستدعي جرعات بالحقن العضلي إضافية بعد الجرعة الأولية، فيمكن إعطاء جرعات لاحقة تصل إلى 10 ملجرام. ومع ذلك، لم يتم تقييم فعالية الجرعات المتكررة من أولانزابين للحقن العضلي في المرضى المضطربين بشكل منهجي في التجارب السريرية الخاضعة للرقابة. أيضًا، لم يتم تقييم سلامة الجرعات اليومية الإجمالية التي تزيد عن 30 مجم، أو 10 ملجرام من الحقن التي تعطى بشكل متكرر أكثر من ساعتين بعد الجرعة الأولية، وبعد 4 ساعات من الجرعة الثانية في التجارب السريرية. قد تترافق الجرعات القصوى من أولانزابين العضلي (على سبيل المثال، 3 جرعات من 10 ملجرام تعطى بفاصل 2 إلى 4 ساعات) مع حدوث انخفاض كبير في ضغط الدم الانتصابي. وبالتالي، يوصى بتقييم انخفاض ضغط الدم الانتصابي لدى المرضى الذين يحتاجون إلى حقن عضلية لاحقة قبل إعطاء أي جرعات لاحقة من أولانزابين للحقن العضلي. لا ينصح بإعطاء جرعة إضافية للمريض الذي يعاني من تغير وضعي مهم سريريًا في ضغط الدم الانقباضي.</p><p dir="RTL">إذا تمت الإشارة إلى العلاج المستمر بأولانزابين سريريًا، فيمكن البدء بجرعة أولانزابين عن طريق الفم بجرعة تتراوح من 5 إلى 20 ملجرام/يوم بمجرد أن يكون ذلك مناسبًا سريريًا.</p><p dir="RTL">الجرعات العضلية في المجموعات الخاصة من المرضى - ينبغي النظر في جرعة قدرها 5 ملجرام / حقنة للمرضى المسنين أو عندما تستدعي العوامل السريرية الأخرى. ينبغي النظر في جرعة أقل قدرها 2.5 ملجرام / حقنة للمرضى الذين قد يعانون من الوهن، أو يكونون عرضة لتفاعلات انخفاض ضغط الدم، أو يكونون أكثر حساسية من الناحية الدوائية لدواء أولانزابين.</p><p dir="RTL">طريقة استخدام أولانزابين للحقن &ndash; أولانزابين للحقن مخصص للاستخدام للحقن العضلي فقط. يجب عدم الحقن عن طريق الوريد أو تحت الجلد. قم بالحقن ببطء، في عمق كتلة العضلات.</p><p dir="RTL">يجب فحص المنتجات الدوائية بصريًا بحثًا عن الجسيمات وتغير اللون قبل تناولها، كلما سمح المحلول والحاوية بذلك.</p><p dir="RTL">توجيهات لإعداد أولانزابين للحقن العضلي مع الماء المعقم للحقن - قم بإذابة محتويات القارورة باستخدام 2.1 مل من الماء المعقم للحقن للحصول على محلول يحتوي على حوالي 5 ملجرام / مل من أولانزابين. يجب أن يبدو المحلول الناتج نقياً وأصفر اللون. يجب استخدام أولانزابين للحقن في العضل مع الماء المعقم للحقن مباشرة (خلال ساعة واحدة) بعد إعادة تحضير المحلول. تخلص من أي جزء غير مستخدم.</p><p dir="RTL">يوفر الجدول التالي أحجام الحقن لتوصيل جرعات مختلفة من أولانزابين للحقن العضلي المعاد تكوينه باستخدام الماء المعقم للحقن.</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td><p dir="RTL"><strong>حجم الحقن/ مل</strong></p></td><td><p dir="RTL"><strong>الجرعة (ملجرام أولانزابين)</strong></p></td></tr><tr><td><p dir="RTL">يتم سحب محتويات القارورة بالكامل</p></td><td><p dir="RTL">10</p></td></tr><tr><td><p dir="RTL">1.5</p></td><td><p dir="RTL">7.5</p></td></tr><tr><td><p dir="RTL">1</p></td><td><p dir="RTL">5</p></td></tr><tr><td><p dir="RTL">0.5</p></td><td style="vertical-align:top"><p>2.5</p></td></tr></tbody></table><p dir="RTL">معلومات عدم التوافق الظاهري &ndash; يجب إعادة تكوين أولانزابين للحقن داخل العضلات فقط باستخدام الماء المعقم للحقن. لا ينبغي الجمع بين أولانزابين للحقن العضلي في حقنة مع حقن الديازيبام لأن الترسيب يحدث عندما يتم خلط هذه المنتجات. لا ينبغي استخدام حقن لورازيبام لإعادة تكوين أولانزابين للحقن داخل العضلات لأن هذا المزيج يؤدي إلى تأخير وقت إعادة التكوين. لا ينبغي دمج أولانزابين للحقن العضلي في حقنة مع حقن هالوبيريدول لأن الرقم الهيدروجيني المنخفض الناتج قد يؤدي إلى تحلل أولانزابين بمرور الوقت.</p><p dir="RTL"><strong>إذا تم إعطاؤك كمية أكبر من بينولانز أكثر من اللازم (جرعة زائدة)</strong></p><p dir="RTL">سيتم إعطاءك هذا الدواء تحت إشراف طبي، لذلك فمن غير المرجح أن يتم إعطاؤك كمية كبيرة منه.</p><p dir="RTL">المرضى الذين تناولوا جرعة زائدة من عقار أولانزابين قد عانوا أيضًا من الأعراض التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبض سريع للقلب، والإثارة/العدوانية، ومشاكل في الكلام، وحركات غير عادية (خاصة الوجه أو اللسان) وانخفاض مستوى الوعي.</p><p dir="RTL"><strong>قد تشمل الأعراض الأخرى ما يلي</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك حاد، نوبات (صرع)، غيبوبة، مزيج من الحمى، تنفس أسرع، تعرق، تصلب العضلات، والنعاس أو النعاس، تنفس أبطأ، طموح، ارتفاع أو انخفاض ضغط الدم، إيقاعات غير طبيعية للقلب.</p><p dir="RTL"><strong>اتصل بطبيبك أو المستشفى على الفور إذا شعرت بأي من الأعراض المذكورة أعلاه. </strong></p><p dir="RTL">لا تتوقف عن علاجك لمجرد أنك تشعر بالتحسن.</p><p dir="RTL">من المهم أن تستمر في تلقي دواء بينولانز طوال المدة التي أخبرك بها طبيبك.</p><p dir="RTL"><strong>إذا فاتتك إحدى الحقن، </strong></p><p dir="RTL">يجب عليك الاتصال بطبيبك لترتيب الحقنة التالية في أقرب وقت ممكن.</p><p dir="RTL"><strong>بينولانز للحقن داخل العضلات: الاضطرابات المرتبطة بالفصام والهوس ثنائي القطب </strong><strong>I</strong></p><p dir="RTL">اختيار الجرعة للمرضى البالغين المضطربين المصابين بالفصام والهوس ثنائي القطب I - تم إثبات فعالية أولانزابين للحقن العضلي في السيطرة على الإثارة في هذه الاضطرابات في نطاق جرعة قدرها 10 ملجرام. الجرعة الموصى بها لهؤلاء المرضى هي 10 ملجرام.</p><p dir="RTL">يمكن النظر في جرعة أقل عندما تستدعي العوامل السريرية ذلك. إذا استمرت الإثارة التي تستدعي جرعات بالحقن العضلي إضافية بعد الجرعة الأولية، فيمكن إعطاء جرعات لاحقة تصل إلى 10 ملجرام. ومع ذلك، لم يتم تقييم فعالية الجرعات المتكررة من أولانزابين للحقن العضلي في المرضى المضطربين بشكل منهجي في التجارب السريرية الخاضعة للرقابة. أيضًا، لم يتم تقييم سلامة الجرعات اليومية الإجمالية التي تزيد عن 30 ملجرام، أو 10 ملجرام من الحقن التي تعطى بشكل متكرر أكثر من ساعتين بعد الجرعة الأولية، وبعد 4 ساعات من الجرعة الثانية في التجارب السريرية. قد تترافق الجرعات القصوى من أولانزابين العضلي (على سبيل المثال، 3 جرعات من 10 ملجرام تعطى بفاصل 2-4 ساعات) مع حدوث انخفاض كبير في ضغط الدم الانتصابي. وبالتالي، يوصى بتقييم انخفاض ضغط الدم الانتصابي لدى المرضى الذين يحتاجون إلى حقن عضلية لاحقة قبل إعطاء أي جرعات لاحقة من أولانزابين للحقن العضلي. لا ينصح بإعطاء جرعة إضافية للمريض الذي يعاني من تغير وضعي مهم سريريًا في ضغط الدم الانقباضي</p><p dir="RTL">إذا تمت الإشارة إلى العلاج المستمر بأولانزابين سريريًا، فيمكن البدء بجرعة أولانزابين عن طريق الفم بجرعة تتراوح من 5 إلى 20 ملجرام/يوم بمجرد أن يكون ذلك مناسبًا سريريًا.</p><p dir="RTL">الجرعات العضلية في المجموعات الخاصة من المرضى- ينبغي النظر في جرعة قدرها 5 ملجرام / حقنة للمرضى المسنين أو عندما تستدعي العوامل السريرية الأخرى. ينبغي النظر في جرعة أقل للمرضى الذين قد يعانون من الوهن، أو يكونون عرضة لتفاعلات انخفاض ضغط الدم، أو يكونون أكثر حساسية من الناحية الدوائية لعقار أولانزابين.</p><p dir="RTL">طريقة استخدام بينولانز لحقن العضلة &mdash; بينولانز مخصص للاستخدام العضلي فقط. يجب عدم الحقن عن طريق الوريد أو تحت الجلد.</p><p dir="RTL">قم بالحقن ببطء، في عمق كتلة العضلات.</p><p dir="RTL">يجب فحص المنتجات الدوائية عن طريق الحقن بصريًا بحثًا عن الجسيمات وتغير اللون قبل تناولها، كلما سمح المحلول والحاوية بذلك.</p><p dir="RTL">توجيهات لتحضير بينولانز للحقن العضلي مع الماء المعقم للحقن - قم بإذابة محتويات القارورة باستخدام 2.1 مل من الماء المعقم للحقن لتوفير محلول يحتوي على حوالي 5 ملجرام / مل من أولانزابين. يجب أن يبدو المحلول الناتج نقياً وأصفرًا. يجب استخدام بينولانز بالحقن داخل العضلات ويتم استخدام المحلول المعاد تكوينه بالماء المعقم للحقن فورًا (خلال ساعة واحدة) بعد إعادة التحضير. تخلص من أي جزء غير مستخدم</p><p dir="RTL">يوضح الجدول التالي أحجام الحقن لتوصيل جرعات مختلفة من أولانزابين للحقن العضلي المعاد تكوينه باستخدام الماء المعقم للحقن</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td><p dir="RTL"><strong>حجم الحقن/ مل</strong></p></td><td><p dir="RTL"><strong>الجرعة (ملجرام أولانزابين)</strong></p></td></tr><tr><td><p dir="RTL">1.5</p></td><td><p dir="RTL">10</p></td></tr></tbody></table><p dir="RTL">معلومات عدم التوافق الظاهري &mdash; يجب إعادة تكوين بينولانز للحقن العضلي فقط باستخدام الماء المعقم للحقن. لا ينبغي دمج بينولانز للحقن العضلي في حقنة مع حقن الديازيبام لأن الترسيب يحدث عندما يتم خلط هذه المنتجات. لا ينبغي استخدام حقن لورازيبام لإعادة تكوين أولانزابين للحقن العضلي لأن هذا المزيج يؤدي إلى تأخير وقت إعادة التكوين. أولانزابين للحقن لا ينبغي دمجه في حقنة مع حقن هالوبيريدول لأن انخفاض الرقم الهيدروجيني (pH) الناتج قد ثبت أنه يؤدي إلى تحلل أولانزابين بمرور الوقت</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو ممرضتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع. أخبر طبيبك فورا إذا كان لديك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; النعاس المفرط، والدوخة، والارتباك، وصعوبة التحدث، وصعوبة المشي، وتصلب العضلات أو الارتعاش، والضعف، والتهيج، والعدوان، والقلق، وزيادة في ضغط الدم، أو التشنجات ويمكن أن تؤدي إلى فقدان الوعي. يمكن أن تحدث هذه العلامات والأعراض في بعض الأحيان نتيجة لدخول بينولانز إلى مجرى الدم بسرعة كبيرة (وهو تأثير جانبي شائع قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; حركة غير عادية (عرض جانبي شائع قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص) بشكل رئيسي في الوجه أو اللسان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; جلطات دموية في الأوردة (أثر جانبي غير شائع قد يؤثر على ما يصل إلى شخص واحد من كل 100 شخص) خاصة في الساقين (تشمل الأعراض التورم والألم والاحمرار في الساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مسببة ألم في الصدر وصعوبة في التنفس. إذا لاحظت أيًا من هذه الأعراض اطلب المشورة الطبية فورًا؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; مزيج من الحمى، سرعة التنفس، التعرق، تصلب العضلات والنعاس (لا يمكن تقدير تكرار هذا التأثير الجانبي من البيانات المتاحة).</p><p dir="RTL">الآثار الجانبية الشائعة الأخرى (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) مع بينولانز تشمل النعاس والألم في موقع الحقن.</p><p dir="RTL">الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص) مع بينولانز تشمل العدوى في موقع الحقن.</p><p dir="RTL">تمت ملاحظة الآثار الجانبية المذكورة أدناه عند إعطاء عقار أولانزابين عن طريق الفم ولكنها قد تحدث بعد تناول بينولانز.</p><p dir="RTL">تشمل الآثار الجانبية الأخرى الشائعة جدًا (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص) زيادة الوزن؛ وزيادة في مستويات البرولاكتين في الدم. في المراحل الأولى من العلاج، قد يشعر بعض الأشخاص بالدوار أو الإغماء (مع بطء معدل ضربات القلب)، خاصة عند النهوض من وضعية الاستلقاء أو الجلوس. عادة ما يتحسن هذا من تلقاء نفسه، ولكن إذا لم يحدث ذلك، أخبر طبيبك.</p><p dir="RTL">الآثار الجانبية الشائعة الأخرى (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) تشمل تغيرات في مستويات بعض خلايا الدم، والدهون المنتشرة وفي العلاج المبكر، زيادات مؤقتة في إنزيمات الكبد. زيادة في مستوى السكريات في الدم والبول. زيادة في مستويات حمض اليوريك وفوسفوكيناز الكرياتين في الدم. الشعور بمزيد من الجوع. دوخة؛ الأرق؛ رعشه؛ حركات غير عادية (خلل الحركة)؛ إمساك؛ فم جاف؛ طفح جلدي؛ فقدان القوة التعب الشديد. احتباس الماء مما يؤدي إلى تورم اليدين أو الكاحلين أو القدمين. حمى؛ الم المفاصل؛ والاختلالات الجنسية مثل انخفاض الرغبة الجنسية لدى الذكور والإناث أو ضعف الانتصاب لدى الذكور.</p><p dir="RTL">الآثار الجانبية الأخرى غير الشائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص) تشمل فرط الحساسية (مثل تورم في الفم والحلق، حكة، طفح جلدي)؛ مرض السكري أو تفاقم مرض السكري، والذي يرتبط أحيانًا بالحماض الكيتوني (الكيتونات في الدم والبول) أو الغيبوبة. النوبات، والتي عادة ما ترتبط بتاريخ من النوبات (الصرع). تصلب العضلات أو تشنجاتها (بما في ذلك حركات العين). متلازمة تململ الساقين؛ مشاكل في الكلام. تأتأة؛ بطء معدل ضربات القلب. حساسية لأشعة الشمس. نزيف من الأنف: انتفاخ البطن. سيلان اللعاب. فقدان الذاكرة أو النسيان. سلس البول؛ عدم القدرة على مثل إنتاج غير طبيعي لحليب الثدي أو نمو غير طبيعي.</p><p dir="RTL">الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 في 1000 شخص) تشمل خفض درجة حرارة الجسم الطبيعية. إيقاعات غير طبيعية للقلب. الموت المفاجئ غير المبرر التهاب البنكرياس مما يسبب آلام شديدة في المعدة والحمى والمرض. مرض الكبد الذي يظهر على شكل اصفرار الجلد والأجزاء البيضاء من العين. مرض عضلي يظهر على شكل آلام وأوجاع غير مبررة. والانتصاب المطول و/أو المؤلم.</p><p dir="RTL">تشمل الآثار الجانبية النادرة جدًا تفاعلات حساسية خطيرة مثل التفاعل الدوائي مع فرط الحمضات والأعراض الجهازية (DRESS). يظهر (DRESS) في البداية كأعراض تشبه أعراض الأنفلونزا مع طفح جلدي على الوجه ثم مع طفح جلدي ممتد وارتفاع في درجة الحرارة وتضخم الغدد الليمفاوية وزيادة مستويات إنزيمات الكبد التي تظهر في اختبارات الدم وزيادة في نوع من خلايا الدم البيضاء (كثرة اليوزينيات).</p><p dir="RTL">أثناء تناول عقار أولانزابين، قد يعاني المرضى كبار السن المصابون بالخرف من السكتة الدماغية، والالتهاب الرئوي، وسلس البول، والسقوط، والتعب الشديد، والهلوسة البصرية، وارتفاع درجة حرارة الجسم، واحمرار الجلد، وصعوبة في المشي. تم الإبلاغ عن بعض الحالات المميتة في هذه المجموعة المحددة من المرضى. في المرضى الذين يعانون من مرض باركنسون، قد يؤدي عقار أولانزابين عن طريق الفم إلى تفاقم الأعراض.</p><p dir="RTL"><strong>ردود الفعل السلبية المرتبطة باستخدام أولانزابين في مرض الفصام</strong><strong>:</strong></p><p dir="RTL">انخفاض ضغط الدم الوضعي، الإمساك، زيادة الوزن، الدوخة، اضطراب الشخصية، تعذر الجلوس.</p><p dir="RTL"><strong>ردود الفعل السلبية المرتبطة باستخدام أولانزابين في الاضطراب ثنائي القطب </strong><strong>I</strong><strong> من النوع الأول (نوبات الهوس أو النوبات المختلطة)</strong></p><p dir="RTL">الوهن، جفاف الفم، الإمساك، عسر الهضم، زيادة الشهية، النعاس، الدوخة، الرعشة.</p><p dir="RTL"><u>الإبلاغ عن ردود الفعل السلبية المشتبه بها</u></p><p dir="RTL">من المهم الإبلاغ عن ردود الفعل السلبية المشتبه بها بعد ترخيص المنتج الطبي. يسمح بالمراقبة المستمرة لتوازن الفوائد / المخاطر للمنتج الطبي. يطلب من المتخصصين في الرعاية الصحية الإبلاغ عن أي ردود فعل سلبية مشتبه بها (انظر التفاصيل أدناه)</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية خطيرا، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك أو الصيدلي.</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong><strong>:</strong></li></ul><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_6" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:92.5pt;margin-top:11.7pt;width:402pt;height:85.5pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="#0d0d0d"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; المركز الوطني للتيقظ الدوائي والسلامة الدوائية</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:91.5pt;margin-top:1.3pt;width:395.5pt;
 height:23.5pt;z-index:251660288;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الرجاء</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بالجهات</strong><strong> </strong><strong>الوطنية</strong><strong> </strong><strong>في</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>دولة</strong></p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; درجة حرارة حفظ المحلول بعد إعادة التكوين (20-25 درجة مئوية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; درجة حرارة حفظ المحلول بعد إعادة التكوين (20-25 درجة مئوية) مع 2.1 مل من الماء المعقم للحقن، سيحتوي كل مل على 5 ملجرام من أولانزابين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; مدة الصلاحية: 24 شهرا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية، المدون على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>المحلول بعد إعادة التكوين: </strong>تم ملاحظة<strong> أن </strong>بينولانز مستقرة لمدة 1 ساعة في درجة حرارة الغرفة (20-25 درجة مئوية) مع الماء المعقم للحقن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أولانزابين.</p><p dir="RTL">تحتوي كل قارورة على أولانزابين 10 ملجرام.</p><p dir="RTL"><strong>المكونات الأخرى هي:</strong></p><p dir="RTL">حمض الطرطريك، مونوهيدرات اللاكتوز، هيدروكسيد الصوديوم، حمض الهيدروكلوريك والماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو بينولانز؟</p><p dir="RTL">مسحوق أو كعكة مجففة بالتجميد باللون الأصفر</p><p dir="RTL">بعد إعادة التحضير - محلول نقي أصفر اللون.</p><p>العبوات المتوفرة:</p><p dir="RTL">يتم توفير حقن بينولانز في قوارير زجاجية أنبوبية الشكل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق</strong><strong>:</strong></p><p><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة ، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p>هاتف و فاكس: 966112268850+</p><p>المصنع:</p><p dir="RTL">اسبيرو فارما المحدودة - الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في مايو 2024 ، نسخة 1. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olmy (Olmesartan Medoxomil Tablets 20mg and 40mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olmy 20 (Olmesartan Medoxomil Tablets 20mg)
Each film coated tablet contains 20mg of Olmesartan Medoxomil Ph.Eur.
Olmy 40 (Olmesartan Medoxomil Tablets 40mg)
Each film coated tablet contains 40mg of Olmesartan Medoxomil Ph.Eur.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet
Olmy 20 (Olmesartan Medoxomil Tablets 20mg)
White to off white, round, biconvex, film coated tablets, debossed with ‘H’ on one side and ‘O3’ on the other side.
Olmy 40 (Olmesartan Medoxomil Tablets 40mg)
White to off white, oval, biconvex, film coated tablets, debossed with ‘H’ on one side and ‘O4’ on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.</p><p>Treatment of hypertension in children and adolescents from 6 to less than 18 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>The recommended starting dose of Olmy is 10 mg once daily. In patients whose blood pressure is not adequately controlled at this dose, the dose of Olmy may be increased to 20 mg once daily as the optimal dose. If additional blood pressure reduction is required, Olmy dose may be increased to a maximum of 40 mg daily or hydrochlorothiazide therapy may be added<strong>.</strong></p><p>&nbsp;</p><p>The antihypertensive effect of Olmy is substantially present within 2 weeks of initiating therapy and is maximal by about 8 weeks after initiating therapy. This should be borne in mind when considering changing the dose regimen for any patient.</p><p>Elderly (65 years or over)</p><p>&nbsp;</p><p>No adjustment of dosage is generally required in elderly people (see below for dose recommendations in patients with renal impairment). If up-titration to the maximum dose of 40 mg daily is required, blood pressure should be closely monitored.</p><p>Renal impairment</p><p>&nbsp;</p><p>The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20 &ndash; 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group. The use of olmesartan medoxomil in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min) is not recommended, since there is only limited experience in this patient group (see sections 4.4, 5.2).</p><p>Hepatic impairment</p><p>&nbsp;</p><p>No adjustment of dosage recommendations is required for patients with mild hepatic impairment. In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment, therefore use is not recommended in this patient group (see sections 4.4 and 5.2). Olmesartan medoxomil should not be used in patients with biliary obstruction (see section 4.3).</p><p>Paediatric population</p><p>&nbsp;</p><p>Children and adolescents from 6 to less than 18 years of age:</p><p>&nbsp;</p><p>The recommended starting dose of olmesartan medoxomil in children from 6 to less than 18 years of age is 10 mg olmesartan medoxomil once daily. In children whose blood pressure is not adequately controlled at this dose, the dose of olmesartan medoxomil may be increased to 20 mg</p><p>&nbsp;</p><p>once daily. If additional blood pressure reduction is required, in children who weigh &ge; 35 kg, the olmesartan medoxomil dose may be increased to a maximum of 40 mg. In children who weigh &lt; 35 kg, the daily dose should not exceed 20 mg.</p><p>Other paediatric population:</p><p>&nbsp;</p><p>The safety and efficacy of olmesartan medoxomil in children aged 1 to 5 years old have not yet been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>Olmesartan medoxomil should not be used in children below 1 years of age because of safety concerns and lack of data in this age group.</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>In order to assist compliance, it is recommended that Olmy tablets be taken at about the same time each day, with or without food, for example at breakfast time. The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Biliary obstruction (see section 5.2).

The concomitant use of Olmy with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see
5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Intravascular volume depletion:</p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of olmesartan medoxomil.</p><p>&nbsp;</p><p>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</p><p><strong>&nbsp;</strong></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with other drugs that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute&nbsp; renal failure. The possibility of similar effects cannot be excluded with angiotensin II receptor antagonists.</p><p>Renovascular hypertension:</p><p><strong>&nbsp;</strong></p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.</p><p>Renal impairment and kidney transplantation:</p><p><strong>&nbsp;</strong></p><p>When olmesartan medoxomil is used in patients with impaired renal function, periodic monitoring of serum potassium and creatinine levels is recommended. Use of olmesartan medoxomil is not recommended in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min) (see sections 4.2, 5.2). There is no experience of the administration of olmesartan medoxomil in patients with a recent kidney transplant or in patients with end-stage renal impairment (i.e. creatinine clearance &lt;12 mL/min).</p><p>Hepatic impairment:</p><p><strong>&nbsp;</strong></p><p>There is no experience in patients with severe hepatic impairment and therefore use of olmesartan medoxomil in this patient group is not recommended (see section 4.2 for dosage recommendations in patients with mild or moderate hepatic impairment).</p><p>Hyperkalaemia:</p><p><strong>&nbsp;</strong></p><p>The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.</p><p>&nbsp;</p><p>The risk, that may be fatal, is increased in elderly people, in patients with renal insufficiency and in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events.</p><p>Before considering the concomitant use of medicinal products that affect the renin-angiotensin- aldosterone system, the benefit risk ratio should be evaluated and other alternatives considered (see also below section &ldquo;Dual blockade of the renin-angiotensin-aldosterone system (RAAS)&rdquo;).</p><p>The main risk factors for hyperkalaemia to be considered are:</p><p>&nbsp;</p><p>-&nbsp; Diabetes, renal impairment, age (&gt; 70 years)</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Combination with one or more other medicinal products that affect the renin-angiotensin- aldosterone system and/or potassium supplements. Some medicinal products or therapeutic class of medicinal products may provoke a hyperkalaemia: salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptors antagonists, non steroidal anti-inflammatory drugs (including selective COX-2 inhibitors), heparin, immunosuppressor as ciclosporin or tacrolimus, trimethoprim.</p><p>-&nbsp;&nbsp;&nbsp; Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g, acute limb ischemia, rhabdomyolysis, extended trauma).</p><p>Close-monitoring of serum potassium in at risk patients is recommended (see section 4.5).</p><p>&nbsp;</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</p><p><strong>&nbsp;</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE- inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>Lithium:</p><p><strong>&nbsp;</strong></p><p>As with other angiotensin-II receptor antagonists, the combination of lithium and olmesartan medoxomil is not recommended (see section 4.5).</p><p>Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy:</p><p><strong>&nbsp;</strong></p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p>Primary aldosteronism:</p><p><strong>&nbsp;</strong></p><p>Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of Olmesartan medoxomil is not recommended in such patients.</p><p>Sprue-like enteropathy:</p><p><strong>&nbsp;</strong></p><p>In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.</p><p>Ethnic differences:</p><p><strong>&nbsp;</strong></p><p>As with all other angiotensin II antagonists, the blood pressure lowering effect of Olmesartan medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p>&nbsp;</p><p>Pregnancy:</p><p><strong>&nbsp;</strong></p><p>Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin II antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>Other:</p><p><strong>&nbsp;</strong></p><p>As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Effects of other medicinal products on olmesartan medoxomil:</p><p>Other antihypertensive medications:</p><p>&nbsp;</p><p>The blood pressure lowering effect of olmesartan medoxomil can be increased by concomitant use of other antihypertensive medications.</p><p>ACE-inhibitors, angiotensin II receptor blockers or aliskiren:</p><p>&nbsp;</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>Potassium supplements and potassium sparing diuretics:</p><p>&nbsp;</p><p>Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium (see section 4.4). Such concomitant use is therefore not recommended.</p><p>Non-steroidal anti-inflammatory drugs (NSAIDs):</p><p>&nbsp;</p><p>NSAIDs (including acetylsalicylic acid at doses &gt; 3g/day and also COX-2 inhibitors) and angiotensin-II receptor antagonists may act synergistically by decreasing glomerular filtration. The risk of the concomitant use of NSAIDs and angiotensin II antagonists is the occurrence of acute renal failure. Monitoring of renal function at the beginning of treatment should be recommended as well as regular hydration of the patient.</p><p>Additionally, concomitant treatment can reduce the antihypertensive effect of angiotensin II receptor antagonists, leading to their partial loss of efficacy.</p><p>Bile acid sequestering agent colesevelam:</p><p>&nbsp;</p><p>Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered (see section 5.2).</p><p>Other compounds:</p><p>&nbsp;</p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed. Coadministration of warfarin and digoxin had no effect on the pharmacokinetics of olmesartan.</p><p>Effects of olmesartan medoxomil on other medicinal products:</p><p><strong>&nbsp;</strong></p><p>Lithium:</p><p>&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and</p><p>&nbsp;</p><p>angiotensin II antagonists. Therefore use of olmesartan medoxomil and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>Other compounds:</p><p>&nbsp;</p><p>Compounds which have been investigated in specific clinical studies in healthy volunteers include warfarin, digoxin, an antacid (magnesium aluminium hydroxide), hydrochlorothiazide and pravastatin. No clinically relevant interactions were observed and in particular olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Olmesartan had no clinically relevant inhibitory effects on in vitro human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4, and had no or minimal inducing effects on rat cytochrome P450 activities. Therefore in vivo interaction studies with known cytochrome P450 enzyme inhibitors and inducers were not conducted, and no clinically relevant interactions between olmesartan and drugs metabolised by the above cytochrome P450 enzymes are expected.</p><p>Paediatric population:</p><p><strong>&nbsp;</strong></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>It is not known if the interactions in children are similar to those in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.45pt;margin-top:14.7pt;width:518.3pt;height:65.9pt;z-index:-251655168;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokecolor="#7c7c7c"
  strokeweight=".72pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.25pt;margin-right:.9pt;
     margin-bottom:0in;margin-left:1.15pt;margin-bottom:.0001pt;text-align:
     justify;line-height:150%'>The use of angiotensin II antagonists is not
     recommended during the first trimester of pregnancy (see section 4.4). The
     use of angiotensin II antagonists is contra-indicated during the 2nd and
     3rd trimester of pregnancy (see sections 4.3 and 4.4).<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="695" height="92" alt="Text Box: The use of angiotensin II antagonists is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II antagonists is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4)." src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>Epidemiological &nbsp;evidence &nbsp;regarding &nbsp;the &nbsp;risk &nbsp;of &nbsp;teratogenicity &nbsp;following &nbsp;exposure &nbsp;to &nbsp;ACE</p><p>inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should</p><p>&nbsp;</p><p>be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Angiotensin II antagonists therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &ldquo;Preclinical Safety Data&rdquo;.)</p><p>Should exposure to angiotensin II antagonists have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken angiotensin II antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Olmesartan is excreted in the milk of lactating rats but it is not known whether olmesartan is excreted in human milk. Because no information is available regarding the use of Olmy during breast-feeding, Olmy is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmy has minor or moderate influence on the ability to drive and use machines. Dizziness&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; <u>Summary of the safety profile:</u></p><p>The most commonly reported adverse reactions during treatment with Olmy are headache (7.7%), influenza-like symptoms (4.0%) and dizziness (3.7%).</p><p>In placebo-controlled monotherapy studies, the only adverse drug reaction that was unequivocally related to treatment was dizziness (2.5% incidence on olmesartan medoxomil and 0.9% on placebo).</p><p>&nbsp;</p><p>The incidence was also somewhat higher on olmesartan medoxomil compared with placebo for hypertriglyceridaemia (2.0% versus 1.1%) and for raised creatine phosphokinase (1.3% versus 0.7%).</p><p><strong><u>Tabulated list of adverse reactions:</u></strong></p><p><strong>&nbsp;</strong></p><p>Adverse reactions from Olmy in clinical trials, post-authorisation safety studies and spontaneous reporting are summarized in the below table.</p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MedDRA</p><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse reactions</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Respiratory,&nbsp;&nbsp;&nbsp;&nbsp; thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Sprue-like enteropathy (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Autoimmune hepatitis*</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Musculoskeletal&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; connective&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue disorders</p></td><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; creatine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phosphokinase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><p>*Cases of autoimmune hepatitis with a latency of few months to years have been reported post- marketing, that were reversible after the withdrawal of olmesartan.</p><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.</p><p><u>Additional information on special populations</u></p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>The safety of olmesartan medoxomil was monitored in 361 children and adolescents, aged 1-17 years old during 2 clinical trials. Whilst the nature and severity of the adverse events are similar to that of the adults, the frequency of the following is higher in the children:</p><p>-&nbsp;&nbsp; Epistaxis is a common adverse event in children (i.e. &ge; 1/100 to &lt; 1/10) that has not been reported in adults.</p><p>-&nbsp; During the 3 weeks of double blind study, the incidence of treatment emergent dizziness and headache nearly doubled in children 6-17 years of age in the high olmesartan medoxomil dose group.</p><p>&nbsp;</p><p>The overall safety profile for olmesartan medoxomil in paediatric patients does not differ significantly from the safety profile in adults.</p><p>Elderly (age 65 years or over)</p><p>&nbsp;</p><p>In elderly people the frequency of hypotension is slightly increased from rare to uncommon. <u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:84.6pt;margin-top:9.7pt;width:383.8pt;height:128.9pt;z-index:-251654144;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16969mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:68.25pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.55pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Toll free phone:<span style='letter-spacing:-.1pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.05pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:blue;text-decoration:
     none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="516" height="176" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only limited information is available regarding overdosage in humans. The most likely effect of overdosage is hypotension. In the event of overdosage, the patient should be carefully monitored and treatment should be symptomatic and supportive.</p><p>No information is available regarding the dialysability of olmesartan.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists, ATC code: C09C A 08.</p><p>&nbsp;</p><p><u>Mechanism of action / Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension via the type 1 (AT1) receptor.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after cessation of therapy.</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment. When used together with hydrochlorothiazide, the reduction in blood pressure is additive and coadministration is well tolerated.</p><p>The effect of olmesartan on mortality and morbidity is not yet known.</p><p>&nbsp;</p><p>The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.</p><p>&nbsp;</p><p>For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.</p><p>For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), &nbsp;non-</p><p>fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular</p><p>mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.</p><p>The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end- stage renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular&nbsp; death&nbsp; in&nbsp; 10&nbsp; (3.5%)&nbsp; patients&nbsp; receiving&nbsp; olmesartan&nbsp; versus&nbsp; 3&nbsp; (1.1%) &nbsp;receiving</p><p>placebo,&nbsp; overall&nbsp; mortality 19&nbsp; (6.7%)&nbsp; versus&nbsp; 20&nbsp; (7.0%),&nbsp; non-fatal&nbsp; stroke&nbsp; 8&nbsp; (2.8%)&nbsp; versus 11</p><p>(3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively. <u>Paediatric population</u></p><p>The antihypertensive effects of olmesartan medoxomil in the paediatric population were evaluated in a randomized, double-blind, placebo-controlled study in 302 hypertensive patients aged 6 to 17 years. The study population consisted of an all black cohort of 112 patients and a</p><p>&nbsp;</p><p>mixed racial cohort of 190 patients, including 38 blacks. The etiology of the hypertension was predominantly essential hypertension (87% of the black cohort and 67% of the mixed cohort). Patients who weighed 20 to &lt;35 kg were randomized to 2.5 mg (low dose) or 20 mg (high dose) of olmesartan medoxomil once daily and patients who weighed &ge;35 kg were randomized to 5 mg (low dose) or 40 mg (high dose) of olmesartan medoxomil once daily. Olmesartan medoxomil significantly reduced both systolic and diastolic blood pressure in a weight-adjusted dose- dependent manner. Olmesartan medoxomil at both low and high doses significantly reduced systolic blood pressure by 6.6 and 11.9 mmHg from the baseline, respectively. This effect was also observed during the 2 weeks randomized withdrawal phase, whereby both mean systolic and diastolic blood pressures demonstrated a statistically significant rebound in the placebo group compared to olmesartan group. The treatment was effective in both, paediatric patients with primary and secondary hypertension. As observed in adult populations, the blood pressure reductions were smaller in black patients.</p><p>In the same study, 59 patients aged 1 to 5 years who weighed &ge;5 kg received 0.3 mg/kg of olmesartan medoxomil once daily for three weeks in an open label phase and then were randomized to receiving olmesartan medoxomil or placebo in a double-blind phase. At the end of the second week of withdrawal, the mean systolic/diastolic blood pressure at trough was 3/3 mmHg lower in the group randomized to olmesartan medoxomil; this difference in blood pressure was not statistically significant (95% C.I. -2 to 7/-1 to 7).</p><p><u>Other information:</u></p><p>&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract.</p><p>No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>&nbsp;</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered drugs is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Total plasma clearance was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p><u>Pharmacokinetics in special populations</u></p><p>&nbsp;</p><p>Paediatric population:</p><p>&nbsp;</p><p>The pharmacokinetics of olmesartan was studied in paediatric hypertensive patients aged 1 to 16 years. The clearance of olmesartan in paediatric patients was similar to that in adult patients when adjusted by the body weight.</p><p>There is no pharmacokinetic information available in renally impaired paediatric subjects.</p><p>&nbsp;</p><p>Elderly (age 65 years or over):</p><p>&nbsp;</p><p>In hypertensive patients, the AUC at steady state was increased by ca 35% in elderly people (65</p><p>&ndash; 75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with the younger age group. This may be at least in part related to a mean decrease in renal function in this group of patients.</p><p>Renal impairment:</p><p>&nbsp;</p><p>In renally impaired patients, the AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.4).</p><p>Hepatic impairment:</p><p>&nbsp;</p><p>After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values were similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).</p><p>Drug interactions</p><p><strong>&nbsp;</strong></p><p>Bile acid sequestering agent colesevelam:</p><p>&nbsp;</p><p>Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine (through functional changes to the kidneys caused by blocking AT1 receptors); reduction in heart weight; a reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit); histological indications of renal damage (regenerative lesions of the renal epithelium, thickening of the basal membrane, dilatation of the tubules). These adverse effects caused by the pharmacological action of olmesartan medoxomil have also occurred in preclinical trials on other AT1 receptor antagonists and ACE inhibitors and can be reduced by simultaneous oral administration of sodium chloride.</p><p>In both species, increased plasma renin activity and hypertrophy/hyperplasia of the juxtaglomerular cells of the kidney were observed. These changes, which are a typical effect of the class of ACE inhibitors and other AT1 receptor antagonists, would appear to have no clinical relevance.</p><p>Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence of chromosome breaks in cell cultures in vitro. No relevant effects were observed in several in vivo studies using olmesartan medoxomil at very high oral doses of up to 2000 mg/kg. The overall data of a comprehensive genotoxicity testing suggest that olmesartan is very unlikely to exert genotoxic effects under conditions of clinical use.</p><p>Olmesartan medoxomil was not carcinogenic, neither in rats in a 2 year study nor in mice when tested in two 6 month carcinogenicity studies using transgenic models.</p><p>In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of offspring was reduced following exposure to olmesartan medoxomil and pelvic dilatation of the kidney was seen after exposure of the dams in late pregnancy and lactation. In common with other antihypertensive agents, olmesartan medoxomil was shown to be more toxic to pregnant rabbits than to pregnant rats, however, there was no indication of a fetotoxic effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp; </strong><strong>Olmesartan Medoxomil</strong></p><p>The other ingredients are: Lactose Monohydrate, Cellulose Microcrystalline, Low-Substituted Hydroxypropyl cellulose, Hydroxypropyl cellulose, Magnesium stearate.</p><p>Film coating composition: HPMC 2910/Hypromellose, Talc, Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu Blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>na</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441, Saudi Arabia
Tel: +966 11 477 2215

Manufacture: Hetero Labs Limited Unit V, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>